On the 18th June
MediLedger announced its blockchain project for the US Food and Drug Administration (FDA) Pilot Program. The project has more than 20 members including leading pharmaceutical companies Pfizer, Genentech (part of Roche), Amgen, Eli Lilly and Gilead. Additionally, it has three of the largest wholesalers McKesson, AmerisourceBergen, and Cardinal Health on board. The big news is the addition of two major retailers in Walgreens and Walmart.
The program aims to produce an interoperable system for traceability in the US pharmaceutical supply chain. The goal is to comply with the Drug Supply Chain Security Act (DSCSA) regulations coming into force in 2023. Before the
FDA set up the pilot program in February, some had concerns that the
DSCSA deadlines would not be met.
San Francisco-based
MediLedger is an open network dedicated to digital solutions in healthcare. The consortium was initiated by
Chronicled, a tech start-up using a private Ethereum based blockchain.
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
